Factors for hepatitis B vaccination and abnormal liver function in Chinese patients with inflammatory bowel disease: A single center experience

Journal of Digestive Diseases

Volumn 14, Issue 11, 2013, Pages 596-603

  Leung, Wai K ^a   Liu, Kevin Sh ^a   Seto, Wai Kay Walter ^a   Chan, Kwok Hung ^b   Tong, Teresa ^a   Yuen, Man Fung ^a   Lai, Ching Lung ^a   Hung, Ivan Fn ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Chinese; Hepatitis B; Thiopurine; Vaccine

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; CHINESE; CROHN DISEASE; ENTERITIS; FEMALE; GENDER; HEPATITIS B; HUMAN; INTESTINE RESECTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; ULCERATIVE COLITIS; VACCINATION;

CHINESE; HEPATITIS B; THIOPURINE; VACCINE;

6-MERCAPTOPURINE; ADULT; AGE FACTORS; AGED; ALANINE TRANSAMINASE; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LIVER; MALE; MIDDLE AGED; RISK FACTORS; VACCINATION;

EID: 84884959684     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12089     Document Type: Article

References (25)

1. Chan HL, Jia J. Chronic hepatitis B in Asia - new insights from the past decade. J Gastroenterol Hepatol 2011; 26 (Suppl 1): 131-137.
2. Xia GL, Liu CB, Cao HL etal. Prevalence of hepatitis B and C virus infections in the general Chinese population: Results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D and E virus infections in China, 1992. Int Hepatol Commun 1996; 5: 62-73.
3. Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med 2007; 147: 58-61.
4. Molodecky NA, Soon IS, Rabi DM etal. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54.e42.
5. Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol 2012; 27: 1266-1280.
6. st century in China: turning challenges into opportunities. J Dig Dis 2012; 13: 195-199.
7. Chow DK, Leong RW, Tsoi KK etal. Long-term follow-up of ulcerative colitis in the Chinese population. Am J Gastroenterol 2009; 104: 647-654.
8. Prideaux L, Kamm MA, De Cruz P etal. Comparison of clinical characteristics and management of inflammatory bowel disease in Hong Kong versus Melbourne. J Gastroenterol Hepatol 2012; 27: 919-927.
9. Hou JK, Velayos F, Terrault N, Mahadevan U. Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 925-932.
10. Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 619-633.
11. Papa A, Felice C, Marzo M etal. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents. J Crohns Colitis 2013; 7: 113-119.
12. Rahier JF, Ben-Horin S, Chowers Y etal; European Crohn's and Colitis Organisation (ECCO). European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3: 47-91.
13. Chevaux JB, Nani A, Oussalah A etal. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis 2010; 16: 916-924.
14. Loras C, Saro C, Gonzalez-Huix F etal; GETECCu (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa). Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 2009; 104: 57-63.
15. Park SH, Yang SK, Lim YS etal. Clinical courses of chronic hepatitis B infection and inflammatory bowel disease in patients with both diseases. Inflamm Bowel Dis 2012; 18: 2004-2010.
16. Wasan SK, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol 2010; 105: 1231-1238.
17. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-753.
18. Lok AS, Mcmahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 3: 661-662.
19. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
20. Gisbert JP, Luna M, González-Lama Y etal. Liver injury in inflammatory bowel disease: long-term follow-up of 786 patients. Inflamm Bowel Dis 2007; 13: 1106-1114.
21. Wong VW, Wong GL, Chu WC etal. Hepatitis B virus infection and fatty liver in the general population. J Hepatol 2012; 56: 533-540.
22. Gisbert JP, Villagrasa JR, Rodríguez-Nogueiras A, Chaparro M. Kinetics of anti-hepatitis B surface antigen titers after hepatitis B vaccination in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 554-558.
23. Gisbert JP, Villagrasa JR, Rodríguez-Nogueiras A, Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol 2012; 107: 1460-1466.
24. Moses J, Alkhouri N, Shannon A etal. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab. Am J Gastroenterol 2012; 107: 133-138.
25. Loras C, Gisbert JP, Minguez M etal; REPENTINA study; GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa) Group. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010; 59: 1340-1346.